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Since the 2008/9 influenza season, the I-MOVE mul-
ticentre case–control study measures influenza vac-
cine effectiveness (VE) against medically-attended 
influenza-like-illness (ILI) laboratory confirmed as 
influenza. In 2011/12, European studies reported a 
decline in VE against influenza A(H3N2) within the 
season. Using combined I-MOVE data from 2010/11 
to 2014/15 we studied the effects of time since vac-
cination on influenza type/subtype-specific VE. We 
modelled influenza type/subtype-specific VE by time 
since vaccination using a restricted cubic spline, 
controlling for potential confounders (age, sex, time 
of onset, chronic conditions). Over 10,000 ILI cases 
were included in each analysis of influenza A(H3N2), 
A(H1N1)pdm09 and B; with 4,759, 3,152 and 3,617 influ-
enza positive cases respectively. VE against influenza 
A(H3N2) reached 50.6% (95% CI: 30.0–65.1) 38 days 
after vaccination, declined to 0% (95% CI: -18.1–15.2) 
from 111 days onwards. At day 54 VE against influenza 
A(H1N1)pdm09 reached 55.3% (95% CI: 37.9–67.9) 
and remained between this value and 50.3% (95% CI: 
34.8–62.1) until season end. VE against influenza B 
declined from 70.7% (95% CI: 51.3–82.4) 44 days after 
vaccination to 21.4% (95% CI: -57.4–60.8) at season 
end. To assess if vaccination campaign strategies 
need revising more evidence on VE by time since vac-
cination is urgently needed.
Introduction
Influenza vaccination is currently the best measure 
available to prevent seasonal influenza infection. In 
most European countries one dose (or two doses for 
children) of seasonal vaccine is recommended from 
late September/October to November/December for 
target groups for vaccination, which may include the 
elderly (either ≥55, ≥60 or ≥65 years of age), clinical 
risk groups, pregnant women, healthcare workers, 
other occupational groups and other groups depending 
on country [1]. In Europe, influenza seasons can last 
until mid-May [2], and it is expected that vaccination 
confers protection to the individual for the duration of 
the season. In thirteen of fifteen reviewed studies on 
the length of vaccine-induced protection among the 
elderly, using anti-haemagglutination antibody titres 
as a proxy for seroprotection levels, seroprotection 
rates lasted at least 4 months after vaccination [3].
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However, in the 2011/12 influenza season various stud-
ies in Europe reported a decrease in influenza vaccine 
effectiveness (VE) against A(H3N2) over time within the 
season [4-7]. In the United States (US), a decrease in VE 
against A(H3N2) with time since vaccination was also 
observed in the 2007/08 influenza season [8].
The observed decrease of VE over time may be 
explained by viral change (notably antigenic drift) 
occurring in the season. Drift in B viruses may be 
slower than in A viruses [9], and A(H3N2) viruses have 
a higher rate of nucleotide substitutions than A(H1N1)
pdm09 viruses [10].
The decrease of VE over time can also be explained 
by a waning of the immunity conferred by the vaccine 
independently from viral changes. If vaccine-induced 
protection wanes during the season, then depending 
on the start and duration of the influenza season, the 
decline of VE may cause increases in overall incidence, 
outbreaks, particularly in residential care facilities, as 
well as hospitalisations and deaths. Changes to vacci-
nation strategies i.e. timing and/or boosters, may be 
needed.
As anti-haemagglutination antibody titres are not 
well defined as a correlate of protection [11,12], vac-
cine efficacy, as measured in trials, or VE measured 
in observational studies may be one way to measure 
vaccine-induced protection. These studies require a 
large sample size to model VE by time since vaccina-
tion and currently, most of the seasonal observational 
studies lack the precision required to provide evidence 
for waning effectiveness.
In this study we pooled data across five post-pandemic 
seasons, namely 2010/11 to 2014/15, from the I-MOVE 
(influenza-monitoring vaccine effectiveness) multicen-
tre case–control studies [2,4,13,14], to obtain a larger 
sample size to study the effects of time since vaccina-
tion on influenza type/subtype-specific VE. We meas-
ured influenza type/subtype-specific VE by time since 
vaccination for the overall season, but also in the early 
phase of the influenza season. Under the hypothesis 
that virological changes are fewer in the early season, 
waning of the vaccine effect should be present regard-
less of phase within the season.
Methods
The I-MOVE multicentre case–control study meth-
ods are described in detail elsewhere [15,16], and are 
based on the European Centre for Disease Prevention 
and Control (ECDC) generic influenza VE case–control 
study protocol [17].
Briefly, several countries (between six and eight 
depending on the season, during the 2010/11 to 
2014/15 study period) carried out a test-negative case–
control study each season to measure influenza VE and 
sent their data to a central hub for pooled analysis. 
Participating practitioners interviewed and collected 
Figure 1
Onset of influenza-like illness (ILI) among (A) influenza 
A(H3N2), (B) A(H1N1)pdm09 and (C) B cases, by season 
and pooled, and dates of vaccinationa of ILI patients, 
by ISO week, I-MOVE multicentre case–control study, 
influenza seasons 2010/11–2014/15
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Patients vaccinated include those vaccinated <15 days before symptom onset.
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naso-pharyngeal specimens from a systematic sample 
of or all patients, depending on age group, consulting 
for influenza like illness (ILI). Practitioners obtained 
clinical and epidemiological information, including vac-
cination status, date of vaccination and vaccine prod-
uct. Cases were patients whose swabs tested positive 
for influenza virus using real-time reverse-transcription 
PCR (RT-PCR), controls were patients whose swabs 
tested negative for influenza virus using RT-PCR.
In the pooled analysis we included patients who con-
sulted their practitioner more than 14 days after the 
start of national or regional seasonal influenza vacci-
nation campaign, who met the criteria for the European 
Union ILI case definition [18], who were swabbed less 
than eight days after symptom onset and who did not 
receive antivirals before swabbing.
For each study site each influenza type/subtype- and 
season-specific study period began at the week of 
onset of the first influenza case and ended at the 
week of onset of the last influenza case after which 
there were at least two consecutive weeks with no fur-
ther influenza-positive cases of that influenza type/
subtype.
We defined patients as vaccinated if they had received 
at least one dose of influenza vaccine more than 14 
days before symptom onset. Patients receiving a dose 
of vaccine < 15 days before symptom onset and receiv-
ing no dose of vaccine were defined as unvaccinated.
For each influenza season and for each influenza type/
subtype-specific analysis we partitioned the influenza 
season into two and created an early and late influenza 
phase. This was based on a mid-season date with an 
equal number of type/subtype-specific cases by dates 
of onset on either side.
For each season, we used logistic regression to com-
pute the odds ratio (OR) of being vaccinated in cases 
and controls. We estimated the type/subtype-adjusted 
influenza VE as (1 minus the OR)*100. Study site was 
modelled as a fixed effect and always included in the 
analysis model. We used Cochran's Q-test and the I2 
index to test for heterogeneity between seasons [19]. 
We pooled individual data across the seasons, always 
including study site and season as a fixed effect in the 
crude or adjusted analysis model. We measured VE 
where sample size was high enough (number of model 
parameters < 10–15% of number of cases) carrying out 
a complete analysis excluding patients with missing 
values for any of the variables in the model measuring 
VE. We included age, sex, presence of a risk factor for 
complications, including chronic conditions, pregnancy 
and obesity where available, and week of symptom 
onset as covariates in the models. Age was modelled 
using a restricted cubic spline, with four or three knots 
depending on sample size with knots specified accord-
ing to Harrell [20].
Figure 2
Pooled-season adjusted vaccine effectiveness against 
influenza A(H3N2) by time since vaccination (days), 
I-MOVE multicentre case–control study, influenza seasons 
2011/12–2014/15
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We measured influenza type/subtype-specific VE for 
the whole influenza season, for the early and late influ-
enza phase, and for all ages and among those aged 60 
years and older.
We coded time since vaccination as date of onset of 
symptoms minus date of vaccination with persons 
not receiving the vaccine coded as ‘0 days’ [21]. We 
modelled time since vaccination using a cubic spline, 
tail-restricted at the upper end, with four knots, two 
a priori at zero and 15 days and then at the 40th and 
90th centile. Those vaccinated less than 15 days before 
symptom onset were modelled as well and were con-
sidered vaccinated for this time since vaccination 
analysis. We included season, study site and the same 
covariates as above in the analysis. We measured type/
subtype-specific VE by time since vaccination for the 
whole influenza season and by early influenza phase 
among all ages. Among those aged 60 years and older 
we measured type/subtype-specific VE by time since 
vaccination for the whole influenza season. We did not 
attempt the modelling where the number of vaccinated 
cases was lower than 50.
In a sensitivity analysis we assessed the shape, 
the coefficients and the model fit using the Aikaike 
Information Criterion (AIC) and Bayesian Information 
Criterion (BIC) of the model, with varying number and 
placement of knots. We further evaluated the inclusion 
of onset weeks in case of collinearity between the two 
time variables: time since vaccination and onset week. 
Where sample size was sufficiently large, we also mod-
elled VE by time since vaccination for each individual 
season and for each influenza type/subtype.
Results
Among the five seasons studied (2010/11 to 2014/15), 
we included four seasons with influenza A(H3N2), four 
seasons with influenza A(H1N1)pdm09 and three sea-
sons with influenza B in the analysis, as these were the 
seasons with sufficient circulation of these influenza 
types/subtypes to carry out our analyses. Influenza 
seasons varied in terms of start, intensity and duration 
by influenza type/subtype (Figure 1). Seventy-nine per-
cent of vaccinations were carried out before the first 
influenza positive case in the study in each country. 
This varied by 40–100% by country.
Among the 2,224 vaccinated patients (9.6%), the 
name of the vaccine product was available for 1,909 
(85.8%). All vaccines were inactivated, with 52.4% 
(n=1,000) of patients vaccinated with egg-derived split 
virion, 24.8% (n=474) with egg-derived subunit, 21.1% 
(n=403) with adjuvanted and 1.7% (n=32) with cell-
derived subunit vaccine. Patients vaccinated within 1.5 
months (45 days) after begin of each season-specific 
vaccination campaign by country were more likely to 
be older than those vaccinated later: median age 64 
(interquartile range (IQR) 46–73), compared with 53 
(IQR 13–69), respectively. They were also more likely to 
have a chronic condition: 61.8% compared with 52.2%.
Influenza A(H3N2)
We included 13,738 ILI cases in the pooled-season 
complete case analysis for influenza A(H3N2), of which 
4,759 (34.6%) were A(H3N2) influenza positive cases. 
Among those aged 60 and over we included 1,775 ILI 
cases, 672 (37.9%) of those were influenza A(H3N2) 
positive. The percentage of records dropped from the 
complete case analysis among all ages due to missing 
data was 5.5%.
Figure 3
Pooled season adjusted vaccine effectiveness against 
influenza A(H1N1)pdm09 by time since vaccination 
(days), I-MOVE multicentre case–control study, influenza 
seasons 2010/11 and 2012/13–2014/15
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The VE by season against influenza A(H3N2) ranged 
between 5.9% and 42.2%. The pooled-season adjusted 
VE (psAVE) was 15.0%, with an I2 index of 27.3%. Among 
those aged 60 years and older, the psAVE was 23.0% 
with an I2 of 0.0% (Table 1).
Mid-season dates partitioning the early and late influ-
enza phase varied by 13 days between seasons (30 
January to 12 February). Among all ages the psAVE was 
32.1% in the early phase and -2.8% in the late phase 
(Table 2). Among those aged 60 years and older the 
psAVE was 36.8% in the early phase and 9.2% in the 
late phase.
When modelling the psAVE by days since vaccination 
against influenza A(H3N2), we see an initial increase to 
a peak, followed by a steady decline. Among all ages 
the psAVE against A(H3N2) by days since vaccination 
initially increased to 50.6% at 38 days since vaccina-
tion (Figure 2). It then declined to 0% at 111 days since 
vaccination, continually declining thereafter.
In the early influenza phase, the psAVE showed a simi-
lar pattern to the overall phase, with a peak of 63.1% at 
day 32. The psAVE then declined to 4.0% at 159 days. 
No patient was vaccinated more than 159 days before 
symptom onset in the early phase.
Among those aged 60 years and older the psAVE 
increased initially to 44.6% at day 45. It then declined 
to 0% at day 140.
Influenza A(H1N1)pdm09
We included 11,385 ILI cases in the pooled-season com-
plete case analysis against influenza A(H1N1)pdm09, 
of which 3,152 (27.7%) tested influenza A(H1N1)pdm09 
positive. Among those aged 60 and over we included 
1,228 ILI cases with 201 (16.4%) A(H1N1)pdm09-posi-
tive cases. Among all ages for the complete case analy-
sis, we dropped 5.9% of records due to missing data.
The VE estimates by season were between 47.5% and 
53.8% against A(H1N1)pdm09 resulting in a psAVE of 
52.2%. There was no statistical heterogeneity between 
season-specific VE estimates (I2 index 0.0%). Among 
those aged 60 years and older, the psAVE was 54.0% 
with an I2 of 39.4% (Table 1).
Mid-season dates partitioning the early and late influ-
enza phase varied by 20 days (14 January to 3 February). 
The psAVE against influenza A(H1N1)pdm09 among all 
ages for the pooled early phase was 50.1% and 52.9% 
for the late phase (Table 2). Crude pooled-season VE 
against A(H1N1)pdm09 among those aged 60 and older 
in the pooled early phase was 44.7% and the AVE was 
61.2% in the late phase, adjusted by month of onset of 
symptoms.
Modelling psAVE against influenza A(H1N1)pdm09 by 
days since vaccination did not suggest any decline in 
psAVE within the season. Among all ages the psAVE 
Figure 4
Pooled season adjusted vaccine effectiveness against 
influenza B by time since vaccination (days), I-MOVE 
multicentre case–control study, influenza seasons 2010/11, 
2012/13 and 2014/15
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initially increased to 55.3% at day 54 (Figure 3). The 
psAVE then remained between 50.0% and 55.3% 
between 31 and 197 days since vaccination. No patients 
were vaccinated more than 197 days before symptom 
onset.
In the early influenza phase, the psAVE against influ-
enza A(H1N1)pdm09 showed a similar pattern to the 
overall phase initially, reaching 61.9% at day 32. After 
that, the psAVE was variable, but never dipped below 
45.2% (day 77). Sample size was too small to calculate 
the psAVE by time since vaccination among those aged 
60 and older.
Influenza B
We included 10,900 ILI cases in the pooled-season 
complete case analysis, of which 3,617 (33.2%) were 
influenza B-positive. Among those aged 60 and over 
we included 1,274 ILI cases, among which 309 (24.3%) 
were influenza B-positive. For the complete case analy-
sis among all ages, we dropped 5.3% of records due to 
missing data.
The season-specific VE against influenza B ranged from 
47.6% to 55.0%, with a psAVE of 50.7%. There was no 
statistical heterogeneity between season-specific VE 
estimates for influenza B (I2 index 0.0%). Among those 
aged 60 years and older, the psAVE was 45.7% against 
influenza B with an I2 of 0.0% (Table 1).
Mid-season dates partitioning the early and late influ-
enza phase varied by 19 days (31 January to 19 February) 
for influenza B. The psAVE against influenza B among 
all ages was 57.5% in the pooled early phase and 
43.4% in the late phase (Table 2). The psAVE against 
influenza B among those aged 60 and older was 46.2% 
in the early phase and 44.5% in the late phase.
Modelling psAVE against influenza B in the overall 
season by days since vaccination showed an initial 
peak, followed by a decline. Among all ages, the psAVE 
against influenza B increased initially to 70.7% at day 
44. It then declined to 21.4% at day 207 (Figure 4).
In the early influenza phase, the psAVE against influ-
enza B peaked at 69.9% at day 39. It then dipped to 
53.7% at day 99. The psAVE increased slightly after day 
99 to 57.9% at day 169.
Among those aged 60 years and older the psAVE 
against influenza B increased initially to 62.7% at day 
49. It then declined to 4.1% at day 197.
Sensitivity analyses
In the sensitivity analyses with varying location of 
knots there was almost no difference in model fit (as 
determined by the AIC/BIC) and the same aspect of 
graphs. Varying the number of knots resulted in little 
difference in model fit. Aspects of the graphs varied 
slightly with different number of knots, but maintained 
the general messages in terms of increase and decline. 
Figure 5
Adjusted vaccine effectiveness against influenza A(H3N2), 
all ages, by season, I-MOVE influenza seasons (A) 
2011/12, (B) 2013/14, (C) 2014/15
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We did not find collinearity, as measured by the vari-
ance inflation factor, between time since vaccination 
and onset weeks. The model fit based on both AIC 
and BIC were substantially better for models including 
onset weeks, compared with without, for all influenza 
type/subtypes.
Sample size permitted modelling VE by time since vac-
cination for some individual seasons: 2011/12, 2013/14 
and 2014/15 against influenza A(H3N2) and 2012/13 
and 2014/15 against influenza B. Similar patterns of 
decline in VE is seen for each individual season as for 
the pooled seasons (Figures 5–6).
Discussion
The pooling of our results across influenza seasons 
suggests a higher VE against influenza A(H3N2) in the 
early than in the late phase among all ages and among 
those aged 60 years and older. This was not observed 
for influenza A(H1N1)pdm09 and only a small decline in 
VE was observed against influenza B among all ages.
Modelling VE against influenza A(H3N2) by time since 
vaccination suggested an initial increase in VE up to 30 
to 45 days since vaccination, which is in line with other 
studies [22]. But then the VE declined to less than 0% 
among all ages and in those 60 years and older in the 
overall season, although the upper CIs remained at 
about 0%. VE by time since vaccination against influ-
enza B also declined after an initial peak among all 
ages and those aged over 60 years; however VE never 
declined to 0%. VE by time since vaccination against 
influenza A(H1N1)pdm09 among all ages remained sta-
ble. VE declined with time since vaccination in the early 
phase for influenza A(H3N2) but not for A(H1N1)pdm09 
and B.
One limitation of this study is that we were unable to 
provide VE by time since vaccination against genetic 
clades of each influenza type/subtype. While there 
appears to be a waning of vaccine effect over time, we 
cannot disentangle to what extent this is due to virus 
change and subsequent non-matching of the vaccine 
or loss of vaccine-induced immunity within the indi-
vidual. Information on genetic clade is available in 
I-MOVE since the 2013/14 season [14]. However, sam-
ples selected for sequencing were few and often not 
representative of the circulating viruses overall. In the 
2015/16 season, I-MOVE will pilot a new method for 
selecting samples for genetic sequencing, using a sys-
tematic sampling approach.
Modelling time since vaccination against genetic clade 
would enable removal of much of the effects of virus 
change over time from the effects due to waning of 
vaccine-induced immunity. In this study, we modelled 
psAVE by time since vaccination restricting to the early 
phase of the influenza seasons, assuming that viro-
logical changes may be fewer in this phase, where we 
still see a decline in VE against influenza A(H3N2). The 
rates and timing of viral mutation during a season are 
unclear, however it has been suggested that signifi-
cant amounts of antigenic drift can occur at any time 
of the season [23]. More information on distribution of 
genetic clades over time is needed.
We pooled data across seasons to increase sample size 
and therefore precision. While there was no statistical 
heterogeneity between season-specific VE estimates, 
there was some variation, particularly for A(H3N2). If 
there is a true decline in vaccine-induced immunity, then 
we expect the shape of the seasonal curve to be simi-
lar to the curve pooled across seasons, although point 
estimates along the curve may vary season on season. 
Single-season models of VE against influenza A(H3N2) 
and against influenza B by time since vaccination show 
similar curves to the pooled-season ones. Sample size 
did not permit modelling of VE against A(H1N1)pdm09 
by season, nor modelling of VE against A(H3N2) or B 
Figure 6
Adjusted vaccine effectiveness against influenza B, all 
ages, by season, I-MOVE, influenza seasons (A) 2012/13, 
(B) 2014/15
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for each season. Even when pooling across seasons, 
sample size remained limited and we were not able to 
estimate psAVE against influenza A(H1N1)pdm09 by 
time since vaccination among those aged 60 and older, 
nor psAVE by time since vaccination in the early season 
among those aged 60 and older against any influenza 
type/subtype. In addition, CIs were wide at the outer 
limits of time since vaccination, but precision was good 
between 60 and 120 days among all ages and for all 
influenza types/subtypes. This corresponds to 2 to 4 
months after vaccination campaigns and is generally 
the period where the main epidemic occurs.
Different vaccines were used not only in the differ-
ent seasons, but also by country and within regions 
within countries. Some individuals were vaccinated 
Table 1
Adjusted vaccine effectiveness against influenza A(H3N2), A(H1N1)pdm09 and B, among all ages and those aged 60 years 
and older, I-MOVE multicentre case–control study, influenza seasons 2010/11–2014/15
Influenza type 
/ subtype for 
analysis
Study 
year
Study sites 
includeda
Weeks 
included in the 
analysis
Mid-season 
date
All ages 60 years and older
Cases; 
vaccinated/ 
Controls; 
vaccinatedb
Adjustedb,c 
VE (95% CI) 
all ages
Cases; 
vaccinated/ 
Controls; 
vaccinatedd
Adjustedd,e 
VE (95% CI) 
all ages
A(H3N2) 
2011/12 FR, ES, HU, IE, IT, PL, PT, RO
Wk 46, 2011–
wk 17, 2012 12 Feb 2012
1,751;197 / 
2,125;249
11.3  
(-15.6–31.9)
251;134 / 
268;131
14.9  
(-33.4–45.8)
2012/13 DE, ES, FR, IE, PL, PT, RO
Wk 43, 2012–
wk 16, 2013 4 Feb 2013
672;46 / 
2,340;212
42.2 (95%CI: 
14.9–60.7)
72;22 / 
190;83
52.8  
(5.5–76.5)
2013/14 DE, ES, HU, IE, PT, RO
Wk 47, 2013–
wk 19, 2014 30 Jan 2014
614;72 / 
1,737;208
5.9 (95%CI: 
-35.6–34.7)
78;38 / 
183;94
40.7  
(-18.0–70.2)
2014/15 DE, ES, HU, IE, IT, PL, PT, RO
Wk 47, 2014–
wk 16, 2015 1 Feb 2015
1,722;225 / 
2,547;355
14.8  
(-5.9–31.4)
270;114 / 
438;199
15.2  
(-20.4–40.3)
Pooled DE, ES, FR, HU, IE, IT, PL, PT, RO
All of the 
weeks 
mentioned 
above
NA 4,759;540 / 8,979;1040
15.0  
(2.6–25.8) 
I2: 27.3; 
p = 0.248
672;308 / 
1103;517
23.0  
(3.2–38.7) 
I2 = 0.0%; 
p = 0.404
A(H1N1)pdm09 
2010/11 FR, ES, HU, IE, IT, PL, PT, RO
Wk 48, 2010–
wk 14, 2011 14 Jan 2011
1,139;39 / 
2,116;227
53.8  
(30.3–69.4)
50;12 / 
284;147
73.1 f 
(44.7–86.9)
2012/13 DE, ES, FR, IE, PL, PT, RO
Wk 47, 2012–
wk 16, 2013 03 Feb-2013
978;44 / 
2,218;214
50.3  
(28.3–65.6)
50;11 / 
204;90
59.1 f 
(14.3–80.5)
2013/14 DE, ES, HU, IE, PT, RO
Wk 50, 2013–
wk 17, 2014 23 Jan 2014
521;34 / 
1,592;203
47.5  
(16.4–67)
42;15 / 
184;96
51.8 f 
(-0.5–76.9)
2014/15 DE, ES, HU, IE, IT, PL, PT, RO
Wk 47, 2014–
wk 16, 2015 31 Jan 2015
514;36 / 
2,201;299
53.3  
(29.6–69.0)
59;20 / 
392;171
22.4 f 
(-44.4–58.4)
Pooled DE, ES, FR. HU, IE, IT, PL, PT, RO
All of the 
weeks 
mentioned 
above
NA 3,152;153 / 8,233;953
52.2  
(41.6–60.9) 
I2 = 0.0%; 
p = 0.975
201;58 / 
1,027;488
54.0  
(38.5–64.0) 
I2 = 39.4%; 
p = 0.176
B 
2010/11 FR, ES, HU, IE, IT, PL, PT, RO
Wk 45, 2010–
wk 13, 2011 31 Jan 2011
754;32 / 
2,131;233
55.0  
(27.4–72.1)
49;18 / 
284;144
42.7f 
(-12.2–70.7)
2012/13 DE, ES, FR, IE, PL, PT, RO
Wk 47, 2012–
wk 18, 2013 15 Feb 2013
1,860;92 / 
2,484;236
49.3  
(32.4–62)
131;38 / 
225;98
39.9  
(-3.4–65)
2014/15 DE, ES, HU, IE, IT, PL, PT, RO
Wk 42, 2014–
wk 19, 2015 19 Feb 2015
1,002;74 / 
2578;354
47.6  
(28.4–61.7)
129;33 / 
441;195
53.2  
(19.1–73)
Pooled DE, ES, FR, HU, IE, IT, PL, PT, RO
All of the 
weeks 
mentioned 
above
NA 3,617;198 / 7,283;830
50.7  
(40.5–59.2) 
I2 = 0.0%; 
p = 0.872
309;89 / 
965;445
45.7  
(24.2–61.1) 
I2 = 0.0%; 
p = 0.801
CI: confidence intervals; NA: not applicable; VE: vaccine effectiveness; wk: week.
a DE: Germany, ES: Spain; FR: France; HU: Hungary; IE: Ireland; IT: Italy; PL: Poland; PT: Portugal; RO: Romania.
b Results from complete case analysis. In some analyses, onset weeks dropped from the model, due to only cases/controls in those weeks. 
Numbers of records therefore dropped: For A(H3N2) 2011/12: 11; 2012/13 45; 2013/14: 20; 2014/15: 222; pooled: 68 For A(H1N1)pdm09: 
2012/13: 53; 2014/15: 205; pooled: 152. For B: 2010/11: 1; 2014/15: 152; pooled: 62.
c Adjusted by study site, age (as restricted cubic spline for all analyses except 2014/15 against A(H3N2) where age group is used), sex, 
presence of chronic disease and week of symptom onset. For the pooled-season results, VE is additionally adjusted by season. Results may 
vary to previously published estimates due to different models applied.
d Results from complete case analysis. In some analyses, onset weeks/months dropped from the model, due to only cases/controls in those 
weeks/months: Numbers of records therefore dropped: For A(H3N2) 2011/12: 23; 2012/13 15; 2013/14: 3; 2014/15: 33; pooled: 49. For 
A(H1N1)pdm09: 2012/13: 12; 2014/15: 10; pooled: 59. For B: 2012/13: 6; 2014/15: 31; pooled: 22.
e Adjusted by study site, age (as restricted cubic spline), sex, presence of chronic disease and week/month of symptom onset. For the pooled-
season results, VE is additionally adjusted by season. Results may vary to previously published estimates due to different models applied.
f Crude VE. VE adjusted by study site only
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with adjuvanted vaccine, which may elicit a different 
immune response, particularly in relation to duration 
of protection [24]. While 21% of vaccinated patients 
with known vaccination brand received an adjuvanted 
vaccine, 67% of these were vaccinated with a vaccine 
adjuvanted by aluminium gel phosphate, which has 
been reported to be inferior to emulsion adjuvants in 
other vaccines [25]. With an increase in sample size, 
estimates of psAVE by time since vaccination by group 
of vaccines (split virion, subunit, adjuvanted) could be 
carried out.
Immune response may differ by age group [26], which 
is why we estimated psAVE by time since vaccination 
among those aged 60 and over. PsAVE by time since 
vaccination was similar in this age group as in all ages. 
However, a greater sample size is needed to provide 
more precision, particularly when partitioning by early 
season. A larger sample size is also needed to provide 
estimates for other age groups.
In this study there was no change in VE against influ-
enza A(H1N1)pdm09 by time since vaccination. This is 
in line with a study suggesting protection of monova-
lent A(H1N1) vaccination in children and adults that 
persisted across several seasons [27]. The vaccine 
component for A(H1N1)pdm09 was the same in all 
seasons of the study (A/California/7/2009 (H1N1)-like 
virus), indicating that the virus remained antigenically 
homogenous across these seasons [28].
VE against influenza B declined slightly with time since 
vaccination. The decline of VE by time since vaccination 
in the early influenza season stabilised around day 99 
and the decline was less steep than in the overall sea-
son. This decline may be due to changes in circulat-
ing influenza B lineage towards the end of the season 
rather than a decline in vaccine-induced immunity. 
However single-season estimates from the 2014/15 
season, where influenza B lineage circulation across 
the season is known, do not support this hypothesis. 
In the 2014/15 season, 71.6% (746/1038) of influenza B 
cases had lineage information available, among which 
740 (99.2%) were B/Yamagata, yet we saw a small 
decline over time [29].
VE against influenza A(H3N2) declined considerably 
with time since vaccination. It is also known that this 
subtype undergoes rapid virological change. Our mod-
elling suggests strong decline in AVE with time since 
vaccination in 2011/12, 2013/14 and 2014/15. During 
the 2011/12 and 2014/15 seasons, circulating influ-
enza A(H3N2) viruses showed an imperfect match to 
the vaccine virus; however, during the 2013/14 season 
few characterised A(H3N2) viruses differed antigeni-
cally from the vaccine virus component [30-32]. If the 
decline in psAVE with time since vaccination is due at 
Table 2
Pooled-season adjusted vaccine effectiveness against influenza A(H3N2), A(H1N1)pdm09 and B, among all ages and 
those aged 60 years and older, by early/late influenza phase, I-MOVE multicentre case–control study, influenza seasons 
2010/11–2014/15
Influenza type/subtype Age group Seasona Cases;vacc/ Controls;vaccb Adjusted VE (95%CI)b,c
A(H3N2) 
All ages
Early pooled 2,395;207 / 4,552;490 32.1 (16.3–44.9)
Late pooled 2,364;333 / 4,427;550 -2.8 (-23.5–14.4)
60 years and older
Early pooled 286;109 / 5,17;235 36.8 (9.7–55.8)
Late pooled 386;199 / 585;282 9.2 (-23.5–33.3)
A(H1N1)pdm09 
All ages
Early pooled 1,573;69 / 3,243;346 50.1 (32.2–63.3)
Late pooled 1,579;84 / 4,990;607 52.9 (38.5–64.0)
60 years and older
Early pooledd 86;29 / 412;186 44.7 (7.5–67.0)
Late poolede 115;29 / 674;327 61.2 (37.7–75.8)
B 
All ages
Early pooled 1,829;94 / 4,390;499 57.5 (43.8–67.8)
Late pooled 1,788;104 / 2,893;331 43.4 (26.4–56.4)
60 years and older
Early pooledf 166;50 / 584;273 46.2 (15.8–65.6)
Late pooledf 143;39 / 399;177 44.5 (8.7–66.3)
CI: confidence intervals; VE: vaccine effectiveness. 
a Distinction between early and late season was based on a mid-season date with an equal number of type/subtype-specific cases by dates of 
onset on either side.
b Results from complete case analysis. In some analyses, onset weeks/months dropped from the model, due to only cases/controls in those 
weeks. Numbers of records therefore dropped: For A(H3N2): all ages early season: 58; all ages late season: 10; 60 years and older early 
season: 38; 60 and older late season: 12. For A(H1N1)pdm09: all ages early season: 152. For B: all ages early season: 62; 60 years and older 
early season: 10; 60 years and older late season: 1.
c Adjusted by study site, age (as restricted cubic spline), sex, presence of chronic disease, week of symptom onset and season, unless 
otherwise specified.
d Crude VE. VE adjusted by study site and season only.
e Adjusted by study site, season and onset month only.
f Adjusted as in b, but using onset month, rather than onset week.
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least in part to waning of vaccine-induced immunity, 
further research is needed to understand why this is 
the case for influenza A(H3N2) in these seasons and B, 
but not for A(H1N1)pdm09.
Previous studies have suggested a within-season 
decline in VE by partitioning time within the season 
or time since vaccination into categories [5,6]. An 
Australian study reported a decline in VE, but it was 
sensitive to the cut-off chosen [33]. In this study we 
modelled time since vaccination as a spline, which pro-
vides added value to the categorical approach. It pro-
vides information on the change in AVE continuously 
for each day between vaccination and onset of symp-
toms. To our knowledge this type of modelling of AVE 
by time since vaccination has not been carried out in 
an influenza VE study before.
While more research is needed to address the effects 
of virological change over the season in the decrease 
in VE over time, this study suggests that there is some 
waning of immunity of the influenza A(H3N2) compo-
nent of the vaccine and to a certain extent the B com-
ponent of the vaccine. These findings underline the 
importance of carrying out influenza VE studies annu-
ally using standardised methodology and in numerous 
sites in order to continually increase our understanding 
of the variability of influenza VE.
Current season influenza VE has been suggested to 
vary by prior season influenza vaccine history [34-36]. 
Our study would benefit from having taken prior sea-
son influenza vaccination into account in the analysis, 
however, sample size for stratification by receipt of 
previous season vaccination is still small despite the 
five year pooling. In addition, it remains uncertain how 
many prior seasons’ vaccination needs to be taken into 
account and cohort studies may be indicated.
A within-season waning of influenza vaccine effect has 
several important health and policy implications. A 
late influenza season may mean an increase in influ-
enza burden, including increased hospitalisations and 
deaths among those vaccinated, within the season. 
Vaccination strategies would need to be reconsidered, 
and could include commencing vaccination campaigns 
later in the year, as is recommended for the 2015/16 
influenza season in Spain [37], providing a booster 
dose of vaccine later in the influenza season or rec-
ommending antiviral treatment among vaccinated in 
an outbreak (for example in a care home) situation. 
Careful consideration of each strategy is needed, as 
for example later vaccination campaigns may result in 
missed opportunities to vaccinate, in case of an early 
season.
We urge other study teams to measure VE by time since 
vaccination, and if possible VE against clades – and to 
pool data to be able to provide results by age group 
and vaccine type/product. Serological studies are also 
needed to complement the VE results. More evidence 
is urgently needed to assess if the time and frequency 
of vaccination campaigns should be reviewed. 
Simultaneously resources should be invested in the 
development of an improved vaccine, to provide higher 
protection levels for all influenza types/subtypes over-
all and across each influenza season.
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National Institute of Research, Bucharest; Spain: Silvia 
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